Ticagrelor and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ticagrelor
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Ticagrelor (Brilinta) and apixaban (Eliquis) are both blood thinners, but they work in different ways. Ticagrelor keeps your platelets from clumping together, while apixaban slows down your body's clotting proteins. When you take them together, their effects add up, which means a higher chance of bleeding, and in some cases that bleeding can be serious.
Sometimes doctors do prescribe these two together on purpose after certain heart procedures. The key is knowing what to watch for. Call your doctor or go to the ER right away if you notice unusual bruising, blood in your urine or stool, black stools, coughing or vomiting blood, or bleeding that won't stop. Your care team can manage this safely by watching you closely.
Effect: Additive pharmacodynamic effect on hemostasis, increasing bleeding risk (potentially serious/fatal). Neither agent is a prodrug; the interaction is PD, not PK-based.
- Direction: Ticagrelor (P2Y12 platelet inhibition) plus apixaban (direct factor Xa inhibition) additively impair hemostasis.
- Evidence: Theoretical; severity rated major. Onset unspecified.
- Management: Promptly evaluate any signs/symptoms of blood loss. Discontinue apixaban with active pathological hemorrhage. Apixaban PD effect persists >=24 h after last dose. Andexanet alfa reverses anti-FXa activity; PCC, aPCC, or rFVIIa may be considered. During PCC use, PT/INR/aPTT and anti-FXa monitoring are not useful. Activated charcoal reduces apixaban absorption.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
The combined use of apixaban with antiplatelet drugs raises bleeding risk 1. In a patient receiving both anticoagulants and antiplatelet agents at the same time, any indications or manifestations of blood loss should be assessed without delay 2. Apixaban must be stopped in patients experiencing active pathological hemorrhage. Instruct patients about the signs and symptoms of blood loss, advising them to report these immediately or present to an emergency room. Apixaban should be discontinued in patients with active pathological bleeding. A reversal agent for the anti-factor Xa activity of apixaban is available. The pharmacodynamic effect of apixaban is anticipated to remain for a minimum of 24 hours following the final dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, evaluating apixaban's anticoagulant effect through a clotting assay (PT, INR, or aPTT) or anti-factor Xa (FXa) activity provides no benefit and is not advised. The absorption of apixaban is diminished by activated oral charcoal, which consequently reduces apixaban plasma concentration 1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
These medicines may be used together deliberately, so do not stop either one on your own. The main job for you and your care team is to catch bleeding early.
- Learn the warning signs: unusual bruising, blood in urine or stool, black or tarry stools, pink or red urine, coughing up or vomiting blood, or bleeding that will not stop.
- Report these to your pharmacist or doctor immediately, or go to an emergency room.
- Your care team may monitor you more closely and will individualize your regimen for your situation.
Reassuringly, a reversal agent for apixaban is available if a serious bleed occurs.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical study involving high-risk patients after an acute coronary syndrome who were treated with aspirin or with aspirin plus clopidogrel (APPRAISE-2) was stopped ahead of schedule because bleeding occurred more often with apixaban than with placebo. Among patients on single antiplatelet therapy, the rate of ISTH major bleeding was 2.8% per year with apixaban compared with 0.6% per year with placebo, while among patients on dual antiplatelet therapy it was 5.9% per year with apixaban compared with 2.5% per year with placebo 1.
b) Among patients taking apixaban, adding aspirin raised the bleeding risk from 1.8% per year to 3.4% per year, and adding both aspirin and warfarin raised the bleeding risk from 2.7% per year to 4.6% per year in a clinical study (ARISTOTLE); use of dual antiplatelet therapy alongside apixaban was limited (2.3%) in this study 1.
c) A retrospective study found that combining a direct oral anticoagulant (DOAC) with antiplatelet therapy (APT; n=78) versus DOAC therapy alone (n=329) did not significantly change the occurrence of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were mainly Caucasian men with a mean age of 63.7 years. Those receiving concurrent APT had significantly higher mean body mass index (30.7 vs 28.4) and mean CHA2DS2-VASc score (4.28 vs 3.85), and were more likely to have diabetes (26.9% vs 17.3%) than those on DOAC monotherapy. The DOACs were prescribed for VTE treatment or atrial fibrillation and consisted of apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was used in 94.9% (74 patients), with aspirin 81 mg once daily being the most common regimen (69 patients). Additional APT regimens comprised aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg plus clopidogrel 75 mg daily (4 patients) 3.
Common questions
Can I take Ticagrelor and Apixaban together?
Taking ticagrelor and apixaban together adds up their blood-thinning effects and raises your bleeding risk, so keep taking both as prescribed but watch closely for signs of bleeding and report them right away. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ticagrelor and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Ticagrelor and Apixaban interaction managed?
These medicines may be used together deliberately, so do not stop either one on your own. The main job for you and your care team is to catch bleeding early. Learn the warning signs: unusual bruising, blood in urine or stool, black or tarry stools, pink or red urine, coughing up or vomiting blood, or bleeding that will not stop. Report these to your pharmacist or doctor immediately, or go to an em… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Ticagrelor or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
Keep reading about Ticagrelor
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist